In patients with advanced, EGFR-mutant NSCLC, PD-L1 expression is found in more than 50% of cases31, but EGFR-mutant NSCLC has a poor response to anti-PD-1/PD-L1 treatment32. Here, PDCD1 is linked to non-small cell lung carcinoma.